Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI-6129 in R/R T-ALL and AML
NCT05519527Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2022
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 1, open-label trial of STI-6129 in t-cell acute lymphoblastic leukemia (T-ALL) and acute myeloid leukemia (AML) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Severity of Adverse Events at 1 year, Maximum Tolerated Dose and 1 more. Planned start Aug 2022; status: withdrawn.
02
Drugs
STI-6129
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05519527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05519527.